

Indoco Remedies soars on getting final nod for Rivaroxaban Tablets

13-Aug-2025 12:21 Hrs IST

Indoco Remedies is currently trading at Rs. 296.80, up by 5.20 points or 1.78% from its previous closing of Rs. 291.60 on the BSE.

The scrip opened at Rs. 292.30 and has touched a high and low of Rs. 309.50 and Rs. 289.60 respectively. So far 4813 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 385.50 on 12-Sep-2024 and a 52 week low of Rs. 190.00 on 28-Feb-2025.

Last one week high and low of the scrip stood at Rs. 309.50 and Rs. 280.15 respectively. The current market cap of the company is Rs. 2731.00 crore.

The promoters holding in the company stood at 58.90%, while Institutions and Non-Institutions held 20.18% and 20.92% respectively.

Indoco Remedies has received final approval of its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg, to market a generic equivalent to the reference listed drug (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen), from U.S. Food and Drug Administration (USFDA).

Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg and 20 mg are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xarelto Tablets, 2.5 mg, 10 mg, 15 mg and 20 mg, of Janssen Pharmaceuticals, Inc. (Janssen). Rivaroxaban Tablets USP, will be manufactured by Indoco Remedies at their manufacturing facility located at Verna Industrial Area, Verna, Goa in India. Rivaroxaban is used for the treatment of venous thromboembolism (VTE).

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.